Heterogeneous subgroups in human neuroblastoma for clinically relevant risk stratification

Area of Science:

• Pediatric Oncology
• Cancer Genomics
• Tumor Heterogeneity

Background:

• Neuroblastoma is a heterogeneous pediatric cancer with variable prognosis.
• Nation-wide mass-screening (MS) in Japan detected most neuroblastomas, including regressing tumors, between 1985-2003.
• Understanding neuroblastoma heterogeneity is crucial for accurate risk stratification.

Purpose of the Study:

• To evaluate the heterogeneity of neuroblastoma subgroups.
• To analyze the age distribution of neuroblastoma incidence using a multi-gene target model.
• To propose a model explaining neuroblastoma's diverse clinical courses.

Main Methods:

• Analysis of 4,209 neuroblastoma patient cases diagnosed between 1971-1995.
• Comparison of cases registered during 1985-1995 with those from 1971-1980.
• Application of a multi-gene target model simulating tumor suppressor genes, oncogenes, and differentiation genes.

Main Results:

• Neuroblastoma incidence distribution revealed four prenatal age groups (20-40, 40-50, 60-90, 160-200 weeks).
• Post-natal clinical neuroblastoma was classified into three age groups: 0-6 months (benign), 1-2 years (malignant), and 3-4 years (malignant).
• The model qualitatively explained one favorable and two unfavorable neuroblastoma prognosis subgroups.

Conclusions:

• A multi-gene model can explain the heterogeneity of neuroblastoma.
• Neuroblastoma can be categorized into distinct subgroups based on age at diagnosis, correlating with prognosis.
• Age-based cutoffs are recommended for clinically relevant risk stratification of heterogeneous neuroblastoma subgroups.